Comparison of Intravitreal Bevacizumab Upload Followed by a Dexamethasone Implant versus Dexamethasone Implant Monotherapy for Retinal Vein Occlusion with Macular Edema

Episode von Medizin - Open Access LMU - Teil 19/22 von Ludwig-Maximilians-Universität München · 1. Januar 2012

Purpose: To compare the efficacy and safety of three intravitreal bevacizumab upload injections followed by a dexamethasone implant versus dexamethasone implant monotherapy in eyes with macular edema due to retinal vein occlusion. Methods: Sixty-four eyes of 64 patients were included in this prospective, consecutive, nonrandomized case series: group 1 consisted of 38 patients (22 with central retinal vein occlusion, CRVO, 16 with branch retinal vein occlusion, BRVO) treated using a dexamethasone implant (Ozurdex) alone; group 2 consisted of 26 patients (14 CRVO, 12 BRVO) treated with three consecutive intravitreal bevacizumab injections at monthly intervals followed by a dexamethasone implant. In case of recurrence, both cohorts received further dexamethasone implants. Preoperatively and monthly best corrected visual acuity (BCVA, ETDRS), central retinal thickness (Spectralis-OCT), intraocular pressure, and wide-angle fundus photodocumentation (Optomap) were performed. The primary clinical endpoint was BCVA at 6 months after initiation of therapy. Secondary endpoints were central retinal thickness and safety of the therapy applied. Results: In group 1, an increase in BCVA of 2.5 (+/- 1.6) letters in the CRVO and of 13.0 (+/- 3.2) letters in BRVO patients was seen after 6 months, in group 2 of 5.9 (+/- 0.4) letters (CRVO) and 3.8 (+/- 2.4) letters (BRVO), which was not statistically significant. When comparing the two treatment groups with respect to the type of vein occlusion, there was a significant advantage for BRVO patients for the dexamethasone implant monotherapy (BRVO patients in group 1, p = 0.005). Central retinal thickness showed a significant reduction after 6 months only in patients of group 1, both for CRVO (p = 0.01) and BRVO (p = 0.003). First recurrence after the first dexamethasone implant injection occurred after 3.8 months (mean) in CRVO and 3.5 months in BRVO patients (group 1), versus 3.2 and 3.7 months, respectively, in group 2. In group 1, 63.6% with CRVO and 50% with BRVO showed an increased intraocular pressure after treatment; in group 2, 57.1% with CRVO and 50.0% with BRVO, respectively. Conclusion: In CRVO, there was no difference between the two treatment strategies investigated. However, in BRVO, dexamethasone implant monotherapy was associated with better functional outcome. Copyright (C) 2012 S. Karger AG, Basel

Weitere Episoden von „Medizin - Open Access LMU - Teil 19/22“

• Antimicrobial Peptides and Skin: A Paradigm of Translational Medicine 1. Januar 2012
• Appraisal of WHO guidelines in maternal health using the AGREE II assessment tool. 1. Januar 2012
• Associations between blood glucose and carotid intima-media thickness disappear after adjustment for shared risk factors: the KORA F4 study. 1. Januar 2012
• Aszites, Pfortaderthrombose und hepatische Enzephalopathie bei Leberzirrhose: Aktuelle Therapieempfehlungen 1. Januar 2012
• Bioavailability, Antipsoriatic Efficacy and Tolerability of a New Light Cream with Mometasone Furoate 0.1% 1. Januar 2012
• Block of death-receptor apoptosis protects mouse cytomegalovirus from macrophages and is a determinant of virulence in immunodeficient hosts. 1. Januar 2012
• Body fat free mass is associated with the serum metabolite profile in a population-based study. 1. Januar 2012
• Botulinum Toxin A for the Treatment of Keloids 1. Januar 2012
• Color in context: psychological context moderates the influence of red on approach- and avoidance-motivated behavior. 1. Januar 2012
• Cultured subventricular zone progenitor cells transduced with neurogenin-2 become mature glutamatergic neurons and integrate into the dentate gyrus. 1. Januar 2012
• DRGs in Transfusion Medicine and Hemotherapy in Germany 1. Januar 2012
• Efficacy and Patient-Reported Outcomes of a New Mometasone Cream Treating Atopic Eczema 1. Januar 2012
• Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale 1. Januar 2012
• Evaluation of the burden of unsuspected pulmonary tuberculosis and co-morbidity with non-communicable diseases in sputum producing adult inpatients. 1. Januar 2012
• Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue 1. Januar 2012

Alle Episoden von Medizin - Open Access LMU - Teil 19/22 · Mehr Bildung-Podcasts